The Cambridge Centre for AI in Medicine (CCAIM) is pleased to announce a groundbreaking strategic partnership with leading pharmaceutical companies AstraZeneca, Boehringer Ingelheim, and GSK. This collaboration aims to harness the power of artificial intelligence and machine learning to drive innovation in medical research and improve patient outcomes worldwide.
Key Objectives of the Partnership:
Innovative Research and Development: The partnership will focus on leveraging AI to accelerate drug discovery, optimise clinical trials, and enhance personalised medicine approaches. By integrating CCAIM’s cutting-edge AI capabilities with the extensive research expertise and resources of AstraZeneca, GSK, and Boehringer Ingelheim, the collaboration aims to bring new therapies to patients more efficiently.
Data-Driven Insights: Through cutting-edge AI/ML approaches, the collaboration will enhance mechanistic understanding of complex diseases and discover novel methods to develop new treatments, design clinical trials, and deliver more effective healthcare. These data-driven programmes will enable more precise and targeted interventions, ultimately improving patient care.
Networking Initiatives: By fostering a collaborative environment, CCAIM and its industry sponsors aim to cultivate an outstanding talent pool equipped to tackle future challenges in medical research with AI and machine learning.
This partnership marks a significant milestone in the development of CCAIM 2.0 – a journey towards a deeper integration of AI into medical research and practice. After successfully completing its initial stage, CCAIM furthers its engagement with a wider community, and renewing its close relationship with AstraZeneca and GSK, as well as bringing a new perspective on board with Boehringer Ingelheim, are important steps to reach our goals.
CCAIM, AstraZeneca, Boehringer Ingelheim, and GSK are committed to working together to achieve breakthroughs that will transform the future of healthcare.
About CCAIM: The Cambridge Centre for AI in Medicine (CCAIM) is a leading research institution as part of the University of Cambridge, dedicated to the development and application of artificial intelligence in the field of medicine. CCAIM aims to revolutionise healthcare through innovative research, education, and collaboration with industry partners.
About AstraZeneca: AstraZeneca is a global, science-led biopharmaceutical company that focuses on the discovery, development, and commercialisation of prescription medicines for the treatment of diseases in a wide array therapy area. AstraZeneca is dedicated to transforming the future of healthcare by unlocking the power of what science can do for people, society and the planet.
About Boehringer Ingelheim: Boehringer Ingelheim is working on breakthrough therapies that transform lives, today and for generations to come. As a leading research-driven biopharmaceutical company, the company creates value through innovation in areas of high unmet medical need. Founded in 1885 and family-owned ever since, Boehringer Ingelheim takes a long-term perspective. More than 52,000 employees serve over 130 markets in the three business areas, Human Pharma, Animal Health, and Biopharmaceutical Contract Manufacturing.
About GSK: GSK is a science-led biopharma company that aims to prevent and treat disease with vaccines, specialty and general medicines. GSK focusses on the science of the immune system and advanced technologies, investing in four core therapeutic areas: infectious diseases, HIV, respiratory/immunology, and oncology. Their Ahead Together strategy means intervening early to prevent and change the course of disease, helping to protect people and support healthcare systems.